Monday, 7 May 2012

Potassium Phosphate


Pronunciation: poe-TAS-ee-um FOS-fate
Generic Name: Potassium Phosphate
Brand Name: K-Phos Original


Potassium Phosphate is used for:

Preventing kidney stones. It is also used to increase the effectiveness of certain antibacterial medicines (methenamine mandelate and methenamine hippurate). It may also be used for other conditions as determined by your doctor.


Potassium Phosphate is a urinary acidifier. It works by increasing the amount of acid in the urine, which lowers the pH of the urine. This may reduce the growth of some bacteria in the urine and help dissolve calcium kidney stones.


Do NOT use Potassium Phosphate if:


  • you are allergic to any ingredient in Potassium Phosphate

  • you have infected kidney stones or severe kidney problems

  • you have decreased urination or are unable to urinate

  • you have high levels of phosphate or potassium in the blood

Contact your doctor or health care provider right away if any of these apply to you.



Before using Potassium Phosphate:


Some medical conditions may interact with Potassium Phosphate. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have low blood calcium levels or you are on a potassium-restricted diet

  • if you have a history of heart problems (eg, heart failure), kidney problems, kidney or other urinary stones, certain muscle problems (eg, myotonia congenita, rhabdomyolysis), stomach or bowel problems (eg, inflammation), liver problems, adrenal gland problems (eg, Addison disease), inflammation of the pancreas, or parathyroid problems

  • if you are dehydrated or have rickets, softened or weakened bones, or a urinary tract infection

  • if you have a condition in which your skin is breaking down (eg, severe burns)

Some MEDICINES MAY INTERACT with Potassium Phosphate. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Aldosterone blockers (eg, eplerenone), aliskiren, angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril), potassium-sparing diuretics (eg, triamterene), or potassium supplements because the risk of high potassium levels, possibly with irregular heartbeat or a heart attack, may be increased

  • Digoxin or salicylates (eg, aspirin) because the risk of their side effects may be increased by Potassium Phosphate

This may not be a complete list of all interactions that may occur. Ask your health care provider if Potassium Phosphate may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Potassium Phosphate:


Use Potassium Phosphate as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Potassium Phosphate is usually taken with meals and at bedtime. Ask your doctor when you should take Potassium Phosphate.

  • Do not swallow Potassium Phosphate whole. Dissolve 2 tablets in 6 to 8 oz (180 to 240 mL) of water. Allow the tablets to dissolve for 2 to 5 minutes or more, if necessary. Stir to be sure the medicine is completely dissolved. If any tablet particles do not dissolve, crush them and stir well.

  • If your doctor has told you to use a different dose, ask your pharmacist how much water to use to dissolve the medicine.

  • Do not take antacids that have aluminum, magnesium, or calcium with Potassium Phosphate without checking with your doctor or pharmacist.

  • If you miss a dose of Potassium Phosphate, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Potassium Phosphate.



Important safety information:


  • Potassium Phosphate may cause dizziness. This effect may be worse if you take it with alcohol or certain medicines. Use Potassium Phosphate with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • While taking Potassium Phosphate, the possibility of passing old kidney stones is increased.

  • Check with your doctor before you use a salt substitute or a product that has potassium in it.

  • Lab tests, including kidney function and electrolyte levels (eg, calcium, potassium, phosphorus), may be performed while you use Potassium Phosphate. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • PREGNANCY and BREAST-FEEDING: It is not known if Potassium Phosphate can cause harm to the fetus. If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Potassium Phosphate while you are pregnant. It is not known if Potassium Phosphate is found in breast milk. If you are or will be breast-feeding while you use Potassium Phosphate, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Potassium Phosphate:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Diarrhea; nausea; stomach pain; vomiting.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bone or joint pain; confusion; decreased urination; dizziness; irregular heartbeat; muscle cramps; numbness, tingling, pain, or weakness in the hands or feet; numbness or tingling around the lips; seizures; severe or persistent diarrhea; shortness of breath; unusual tiredness; unusual weakness or heaviness of the legs.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.


Proper storage of Potassium Phosphate:

Store Potassium Phosphate at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Potassium Phosphate out of the reach of children and away from pets.


General information:


  • If you have any questions about Potassium Phosphate, please talk with your doctor, pharmacist, or other health care provider.

  • Potassium Phosphate is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Potassium Phosphate. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

Saturday, 5 May 2012

Elleste Solo 1mg & 2mg







Elleste Solo 1 mg and 2 mg




(estradiol hemihydrate)



Read all of this leaflet carefully before you start using this medicine.


  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, please ask your doctor or pharmacist.

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.



In this leaflet:


  • 1. What Elleste Solo is and what it is used for

  • 2. Before you take Elleste Solo

  • 3. How to take Elleste Solo

  • 4. Possible side effects

  • 5. How to store Elleste Solo

  • 6. Further information




What Elleste Solo Is And What It Is Used For


Elleste Solo is a form of hormone replacement therapy (HRT).


It contains the hormone estradiol hemihydrate, and is one of a group of medicines called estrogen-only preparations. It is not an oral contraceptive.



Why has your doctor given you Elleste Solo?


Elleste Solo treats the symptoms of the menopause (change of life). It is usually given to women who have had a hysterectomy (had their womb removed).


As you approach the menopause, your ovaries gradually produce fewer hormones. This may cause unpleasant symptoms such as hot flushes and sweating. Elleste Solo replaces a hormone which you lose during the menopause and prevents or relieves any unpleasant symptoms.


You doctor will aim to give you the lowest dose required to treat your symptoms.


Other changes in your bones may also take place over a longer time. These changes can lead to an increased risk of your bones breaking or cracking. If you are at an increased risk of fractures due to osteoporosis (thinning of the bones) but are unable to take other treatments or if other therapies prove to be ineffective, Elleste Solo 2 mg may also be used for this purpose. Your doctor should discuss all the available options with you.





Before You Take Elleste Solo


Elleste Solo may not be suitable for all women.


Read the list below.




DO NOT take Elleste Solo, if you have, or have ever had:


  • a blood clot in a vein in your leg or anywhere else (a "deep vein thrombosis");

  • a blood clot that has travelled to your lung or another part of the body (an "embolus");

  • narrowed or blocked arteries possibly leading to angina and heart disease;

  • breast or womb cancer;

  • unexplained vaginal bleeding;

  • liver problems, for example, jaundice (yellowing of the skin or eyes);

  • porphyria (a rare inherited blood disease);

  • untreated endometrial hyperplasia (an overgrowth of the lining of your womb).

Also do not take Elleste Solo if you:


  • are pregnant or think you could be pregnant;

  • are breast-feeding;

  • have ever had an allergic reaction to any of the ingredients in Elleste Solo (see Section 6).

Elleste Solo contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.



Sunset yellow colouring in Elleste Solo 2mg can cause allergic-type reactions, including asthma. This allergy is more common in people who are allergic to aspirin.




Safety of HRT



As well as benefits, HRT has some risks which you need to consider when you're deciding whether to take it, or whether to carry on taking it.





Take special care with Elleste Solo Tablets


Elleste Solo might have an effect on various processes in your body. HRT should only be started for symptoms that reduce your quality of life.





Medical check-ups



Before you start taking HRT, your doctor should ask about your own and your family's medical history. Your doctor may decide to examine your breasts and/or your abdomen, and may do an internal examination - but only if these examinations are necessary for you, or if you have any special concerns.



Once you've started on HRT, you should:


  • see your doctor for regular check-ups (at least once a year). At these check-ups, your doctor may discuss with you the benefits and risks of continuing to take HRT;


  • go for regular breast screening and cervical smear tests;


  • regularly check your breasts for any changes such as dimpling of the skin, changes in the nipple, or any lumps you can see or feel.




Effects on your heart or circulation



Heart disease:



HRT is not recommended for women who have heart disease, now or in the past. If you have ever had heart disease, talk to your doctor to see if you should be taking HRT.


HRT will not help to prevent heart disease.


Studies with one type of HRT (containing conjugated estrogen plus the progestogen MPA) have shown that women may be slightly more likely to get heart disease during the first year of taking the medication. For other types of HRT, the risk is likely to be similar, although this is not yet certain.




If you get:


  • a pain in your chest that spreads to your arm or neck


See a doctor as soon as possible and do not take any more HRT until your doctor says you can. This pain could be a sign of heart disease.



Stroke:


Recent research suggests that HRT slightly increases the risk of having a stroke. Other factors that can increase the risk of stroke include:


  • getting older

  • high blood pressure

  • smoking

  • drinking too much alcohol

  • an irregular heartbeat.


If you are worried about any of these things, or if you have had a stroke in the past, talk to your doctor to see if you should take HRT.




Compare


Looking at women in their 50s who are not taking HRT - on average, over a 5-year period, 3 in 1000 would be expected to have a stroke.


For women in their 50s who are taking HRT, the figure would be 4 in 1000.


Looking at women in their 60s who are not taking HRT - on average, over a 5-year period, 11 in 1000 would be expected to have a stroke.


For women in their 60s who are taking HRT, the figure would be 15 in 1000.




If you get:


  • unexplained migraine-type headaches, with or without disturbed vision


See a doctor as soon as possible and do not take any more HRT until your doctor says you can. These headaches may be an early warning sign of a stroke.



Blood clots:


HRT may increase the risk of blood clots in the veins (also called deep vein thrombosis, or DVT), especially during the first year of taking it.


These blood clots are not always serious, but if one travels to the lungs, it can cause chest pain, breathlessness, collapse or even death. This condition is called pulmonary embolism, or PE.


DVT and PE are examples of a condition called venous thromboembolism, or VTE.



You are more likely to get a blood clot if you:


  • are seriously overweight

  • have had a blood clot before or have a close family member who has had blood clots

  • have had one or more miscarriages

  • have any blood clotting problem that needs treatment with a medicine such as warfarin

  • are off your feet for a long time because of major surgery, injury or illness

  • have a rare condition called systemic lupus erythematosus (SLE).


If any of these apply to you, talk to your doctor to see if you should take HRT.




Compare


Looking at women in their 50s who are not taking HRT - on average, over a 5-year period, 3 in 1000 would be expected to get a blood clot.


For women in their 50s who are taking HRT, the figure would be 7 in 1000.


Looking at women in their 60s who are not taking HRT - on average, over a 5-year period, 8 in 1000 would be expected to get a blood clot.


For women in their 60s who are taking HRT, the figure would be 17 in 1000.




The following may be signs of blood clot if you get:


  • painful swelling in your leg

  • sudden chest pain

  • difficulty breathing


See a doctor as soon as possible and do not take any more HRT until your doctor says you can.



If you're going to have surgery, make sure your doctor knows about it. You may need to stop taking HRT about 4 to 6 weeks before the operation, to reduce the risk of a blood clot.


Your doctor will tell you when you can start taking HRT again.





Effects on your risk of developing cancer



Breast cancer:



Women who have breast cancer, or have had breast cancer in the past, should not take HRT.


Taking HRT slightly increases the risk of breast cancer; as does having a later menopause. Your risk of breast cancer is also higher if you:


  • have a close relative (mother, sister or grandmother) who has had breast cancer

  • are seriously overweight.

The risk for a post-menopausal woman taking estrogen-only HRT for 5 years is about the same as for a woman of the same age who is still having periods over that time and not taking HRT. The risk for a woman who is taking estrogen plus progestogen HRT is higher than for estrogen-only HRT (but estrogen plus progestogen HRT is beneficial for the endometrium, see 'Endometrial cancer' below).


For all kinds of HRT, the extra risk of breast cancer increases the longer you take it, but returns to normal within about 5 years after stopping.




Compare


Looking at women aged 50 who are not taking HRT - on average, 32 in 1000 will be diagnosed with breast cancer by the time they reach the age of 65.


For women who start taking estrogen-only HRT at age 50 and take it for 5 years, the figure will be between 33 and 34 in 1000 (ie an extra 1-2 cases).


If they take estrogen-only HRT for 10 years, the figure will be 37 in 1000 (ie an extra 5 cases).


For women who start taking estrogen plus progestogen HRT at age 50 and take it for 5 years, the figure will be 38 in 1000 (ie an extra 6 cases).


If they take estrogen plus progestogen HRT for 10 years, the figure will be 51 in 1000 (ie an extra 19 cases)




If you notice any changes in your breasts, such as:


  • dimpling of the skin

  • changes in the nipple

  • any lumps you can see or feel


Make an appointment to see your doctor as soon as possible.



Endometrial cancer (cancer of the lining of the womb):



Taking estrogen-only HRT for a long time can increase the risk of cancer of the lining of the womb (the endometrium). Taking a progestogen as well as the estrogen helps to lower the extra risk.


Elleste Solo is an estrogen-only product.



If you still have your womb, your doctor may prescribe a progestogen as well as estrogen. If so, these may be prescribed separately, or as a combined HRT product.



If you have had your womb removed (a hysterectomy), your doctor will discuss with you whether you can safely take estrogen without a progestogen.



If you've had your womb removed because of endometriosis, any endometrium left in your body may be at risk. So your doctor may prescribe HRT that includes a progestogen as well as an estrogen.




Compare


Looking at women who still have a uterus and who are not taking HRT - on average 5 in 1000 will be diagnosed with endometrial cancer between the ages of 50-65.


For women who take estrogen-only HRT, the figure will be between 10 and 60 in 1000 (ie an extra 5 to 55 cases), depending on the dose and how long you take it.


The addition of a progestogen to estrogen-only HRT substantially reduces the risk of endometrial cancer.



If you get breakthrough bleeding or spotting, it's usually nothing to worry about, especially during the first few months of taking HRT.




Make an appointment to see your doctor if the bleeding or spotting:


  • carries on for more than the first few months

  • starts after you've been on HRT for a while

  • carries on even after you've stopped taking HRT

  • It could be a sign that your endometrium has become thicker.


Ovarian cancer


Ovarian cancer (cancer of the ovaries) is very rare, but it is serious. It can be difficult to diagnose, because there are often no obvious signs of the disease.


Some studies have indicated that taking estrogen-only HRT for more than 5 years may increase the risk of ovarian cancer. It is not yet known whether other kinds of HRT increase the risk in the same way.





While you are taking Elleste Solo


Certain diseases sometimes get worse when you are taking hormone replacement therapy. Your doctor may need to check you more closely if you have any of the following.


  • Migraine or severe headache

  • Asthma

  • Gallstones

  • Epilepsy

  • High blood pressure

  • A personal or family history of blood clots

  • Diabetes (see below)

  • Liver problems

  • Heart or kidney problems

  • Endometrial hyperplasia (overgrowth of the lining of your womb)

  • Fibroids in your womb (see below)

  • Endometriosis (where tissue from your womb is found outside the womb)

  • A history of breast cancer in your family

  • Systemic lupus erythematosus (SLE; a chronic inflammatory disease affecting the skin and organs)

  • Otosclerosis (an inherited form of deafness which sometimes gets worse during pregnancy)

  • High levels of lipids in your blood (hypertriglyceridaemia)

Elleste Solo may affect the result of certain laboratory tests, so tell the person taking the sample that you are taking Elleste Solo.


If you have:



  • fibroids (lumps of fibrous and muscular tissue) in your womb, these may increase in size when you are taking Elleste Solo. See your doctor if you have pain or swelling in your abdomen.


  • diabetes, you may need to change the amount of insulin you take. Check your blood glucose level more often until it is steady.


Do i need to use contraception while I am taking Elleste Solo ?


It is important to remember that Elleste Solo is not a contraceptive (the pill).


If you are using the pill or another hormonal contraceptive you will need to use another type of contraceptive. Please discuss this with your doctor.





Taking other medicines with Elleste Solo


Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including over-the-counter medicines.


In particular, tell your doctor if you are using any of the following because they may alter the effects of Elleste Solo:


  • drugs that treat epilepsy, and some anti-infectives (anti-virals and antibiotics) and sedatives.

  • herbal medicines containing St. John's Wort.


  • diabetic drugs, as this product may affect your blood glucose level. If you are being treated for diabetes please let your doctor or pharmacist know that you take Elleste Solo.

If your doctor does not know that your are taking these other medicines, tell him or her before you start taking Elleste Solo.





Pregnancy and breast-feeding


Elleste Solo is for use in post-menopausal women. It should not be taken by pregnant or breast-feeding women.





Driving or using machines


No effects on driving or using machinery have been observed for Elleste Solo.





Important information about some of the ingredients of Elleste Solo Tablets


Elleste Solo contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.



Sunset yellow colouring in Elleste Solo 2mg can cause allergic-type reactions, including asthma. This allergy is more common in people who are allergic to aspirin.





How To Take Elleste Solo



If you are still having regular periods, take your first tablet on the first day of bleeding.



If you are not having regular periods, you can start straight away.


  • Take one tablet each day. You can take the tablet at a time of the day that suits you. But it is best to take it about the same time each day.

  • Swallow the tablets whole, with some water.

  • Follow the direction of the arrows on the pack and take a tablet each day until the pack is empty. All the tablets are the same.

  • The days of the week are marked on the strip to help you to remember to take one each day.

  • When you finish a foil strip, start a new strip on the next day.


Changing from another type of HRT


If you are changing from another type of HRT, start taking Elleste Solo when you finish the pack of HRT you are taking at the moment.


If your doctor gives you instructions on changing from another type of HRT you should follow these instructions. If you have any doubts you should contact your doctor.



Will I have periods?


If you have not had a hysterectomy, and you are also taking a progestogen, you will probably have a monthly bleed. In the first few months you may get irregular bleeding. However, if this carries on you should tell your doctor.




If you forget to take a tablet


Take the tablet as soon as you remember, and take the next one at the normal time.


If you have missed your tablet by more than 12 hours, dispose of this tablet safely and take the next one at the normal time. If you have not had a hysterectomy you may experience breakthrough bleeding or spotting.





If you take more than you should


There should be no problems, but you may feel sick or actually be sick. If you are worried contact your doctor. Take the usual table the following day.





Possible Side Effects


Like all medicines, Elleste Solo can cause side effects, although not everybody gets them. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.



Stop taking the tablets immediately and tell your doctor if:


  • you become jaundiced (yellowing of the skin or eyes);

  • you have itching all over your body;

  • you have an unusual, severe or prolonged headache;

  • your sight is affected in any way;

  • you find it difficult to speak;

  • any part of your body suddenly feels weak or numb;

  • there is a chance that you could be or could become pregnant; or

  • you develop any of the conditions listed under "Before you take Elleste Solo".


During the first few months you may feel sick, have headaches, or your breasts may be painful or increase in size. These side effects should lessen as your body gets used to the medicine.




You may also get the following side effects:



Common: feeling sick, stomach cramps, headache, an increase in size of fibroids in the womb, breakthrough bleeding, changes in weight, oedema (swelling) of legs, breast tenderness and enlargement, mood changes, changes in sex drive.



Uncommon: indigestion, being sick, flatulence, gallstones and gallbladder disease, feeling dizzy, migraine, vaginal thrush, increase in blood pressure, leg cramps, breast cancer (please refer to the earlier section on breast cancer).



Rare: loss of hair from the scalp, increase in body and facial hair, itchiness, rashes, thromboembolic disease (please refer to the earlier section on the effects of HRT on the heart and circulation).



Very rare: heart disease (please refer to the earlier section on the effects of HRT on the heart and circulation), stroke, chloasma (brown patches on the skin), red swellings on the skin.


HRT will not prevent memory loss. In one study of women who started using combined HRT after the age of 65, a small increase in the risk of dementia was observed.





How To Store Elleste Solo


Keep out of the reach and sight of children.


Do not store above 25°C. Store in the original package.


Don't take Elleste Solo after the 'expiry date' shown on the box.


If your tablets are out of date, take them to your pharmacist who will dispose of them safely.




Further Information



What Elleste Solo contains


  • Elleste Solo 1mg tablets contain the active ingredient 1 milligram estradiol (as hemihydrate).

  • Elleste Solo 2mg tablets contain the active ingredient 2 milligrams estradiol (as hemihydrate).

    (The estradiol hemihydrate used to make Elleste Solo does not come from animals).

  • The tablets also contain: lactose monohydrate, maize starch, povidone, talc, magnesium stearate, macrogol 400, titanium dioxide (E171), and hypromellose (E464).

  • Elleste Solo 2mg has the extra ingredient sunset yellow (E110) (see also the warning at the end of section 2).



What Elleste Solo looks like and contents of the pack


Elleste Solo 1mg tablets are white film-coated tablets with an embossing.


Elleste Solo 2mg tablets are orange film-coated tablets with an embossing.


They are supplied in three blister strips in each pack. Each strip contains 28 tablets.




Marketing Authorisation Holder



Meda Pharmaceuticals Ltd

Skyway House

Parsonage Road

Takeley

Bishop's Stortford

CM22 6PU

UK




Manufacturer



Piramal Healthcare UK Ltd.

Whalton Road

Morpeth

Northumberland

NE61 3YA

UK




This leaflet was last approved in
October 2009.


If you have any comments on the way this leaflet is written, please write to



Meda Pharmaceuticals Ltd

Skyway House

Parsonage Road

Takeley

Bishop's Stortford

CM22 6PU

UK


5012/PIL6 5013/PIL6


20701187





Sentinel Flavor Tabs





Dosage Form: FOR ANIMAL USE ONLY
Sentinel Flavor Tabs

SENTINEL® (milbemycin oxime/lufenuron) Flavor Tabs®


The palatable once-a-month prescription tablet that prevents heartworm disease and flea populations in dogs and puppies. SENTINEL® (milbemycin oxime/lufenuron) Flavor Tabs® also control flea populations and adult hookworms, and remove and control adult roundworm and whipworm infection in dogs and puppies.



Caution


Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.



Warnings


Not for human use. Keep this and all drugs out of the reach of children.



Description


Sentinel Flavor Tabs are available in four tablet sizes in color-coded packages for oral administration to dogs and puppies according to their weight. (See Dosage Section). Each tablet is formulated to provide a minimum of 0.23 mg/pound (0.5 mg/kg) of milbemycin oxime and 4.55 mg/pound (10 mg/kg) body weight of lufenuron.


Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 (C32H45NO7, MW 555.71) and 20% A3 (C31H43NO7, MW 541.68). Milbemycin oxime is classified as a macrocyclic anthelmintic.


Lufenuron is a benozylphenylurea derivative with the following chemical composition: N-[2,5-dichloro-4-(1,1,2,3,3,3, - hexafluoropropoxy)-phenylaminocarbonyl]-2,6- difluorobenzamide (C17H8Cl2F8N2O3, MW 511.15). Benzozylphenylurea compounds, including lufenuron, are classified as insect development inhibitors (IDIs).



Mode of Action


Milbemycin oxime, one active ingredient in Sentinel Flavor Tabs, is a macrocyclic anthelmintic which is believed to act by interfering with invertebrate neurotransmission. Milbemycin oxime eliminates the tissue stage of heartworm larvae and the adult stage of hookworm (Ancylostoma caninum), roundworm (Toxocara canis and Toxascaris leonine) and whipworm (Trichuris vulpis) infestations when administered orally according to the recommended dosage schedule.


Lufenuron, the other active ingredient, Sentinel Flavor Tabs, is an insect development inhibitor which breaks the flea life cycle by inhibiting egg development. Lufenuron’s mode of action is interference with chitin synthesis, polymerization and deposition. Lufenuron has no effect on the adult flea. After biting a lufenuron-treated dog, the female flea ingests a blood meal containing lufenuron which is subsequently deposited in her eggs. Lufenuron prevents most flea eggs from hatching or maturing into adults and thus prevents and controls flea populations by breaking the life cycle. (See Efficacy).



Indications


Sentinel Flavor Tabs are indicated for use in dogs and puppies, four weeks of age and older, and two pounds body weight or greater. Sentinel Flavor Tabs are also indicated for the prevention of heartworm disease caused by Dirofilaria immitis, for the prevention and control of flea populations, the control of adult Ancylostoma caninum (hookworm), and the removal and control of adult Toxocara canis and Toxocara leonina (roundworm) and Trichuris vulpis (whipworm) infections.


Lufenuron controls flea populations by preventing the development of flea eggs and does not kill adult fleas. Concurrent use of adulticide product may be necessary for adequate control of adult fleas.


Sentinel Flavor Tabs may be used con currently with CAPSTAR® (nitenpyram) Tablets to provide a Flea Management System that kills adult fleas and prevents flea eggs from hatching. Please see the Supplemental Veterinary Package Insert provided with this product for information about concurrent use of the two products,


Without concurrent use of an adulticide, adequate flea control may not be achieved in dogs that have repeated exposure to flea infested animals or environments.



Precautions


Do not use in puppies less than four weeks of age and less than two pounds of body weight. Prior to administration of Sentinel Flavor Tabs, dogs should be tested for existing heartworm infections. Infected dogs should be treated to remove adult heartworms and microfilariae prior to initiating treatment with Sentinel Flavor Tabs. Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy have been noted in some treated dogs carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.


Sentinel Flavor Tabs immediately break the flea life cycle by inhibiting egg development. However, pre-existing flea populations may continue to develop and emerge after treatment with Sentinel Flavor Tabs has begun. Based on results of clinical studies, this emergence generally occurs during the first 30-60 days. Therefore, noticeable control may not be observed until several weeks after dosing when a pre-existing infestation is present. Cooler geographic areas may have longer lag periods due to a prolonged flea life cycle. The concurrent use of an approved adulticide, like CAPSTAR may be employed depending on the severity of the infestation.


If a Sentinel Flavor Tabs-treated dog comes in contact with a flea-infested environment, adult fleas may infest the treated animal. These adult fleas are unable to produce viable offspring. The temporary use of an adulticide product may be necessary to kill these adult fleas.



Efficacy: Milbemycin Oxime


Milbemycin oxime provided complete protection against heartworm infection in both controlled laboratory and clinical trials.


In laboratory studies, a single dose of milbemycin oxime at 0.5 mg/kg was effective in removing roundworm, hookworm and whipworm. In well-controlled clinical trials, milbemycin oxime was also effective in removing roundworms and whipworms and in controlling hookworms.



Efficacy: Lufenuron


Lufenuron provided 99% control of flea egg development for 32 days following a single dose of lufenuron at 10 mg/kg in studies using experimental flea infestations. In well-controlled clinical trials, when treatment with lufenuron tablets was initiated prior to the flea season, mean flea counts were lower in lufenuron-treated dogs versus placebo-treated dogs. After 6 monthly treatments, the mean number of fleas on lufenuron-treated dogs was approximately 4 compared to 230 on placebo-treated dogs.


When treatment was initiated during the flea season, lufenuron tablets were effective in controlling flea infestations on dogs that completed the study. The mean flea count per lufenuron-treated dog was approximately 74 prior to treatment but had decreased to 4 after six monthly doses of lufenuron. A topical adulticide was used in the first eight weeks of the study to kill the pre-existing adult fleas.



Safety: Milbemycin Oxime


Milbemycin oxime has been tested safely in over 75 different breeds of dogs, including collies, pregnant females, breeding males and females, and puppies over two weeks of age. In well-controlled clinical field studies 786 dogs completed treatment with milbemycin oxime. Milbemycin oxime was used safely in animals receiving frequently used veterinary products such as vaccines, anthelmintics, antibiotics, steroids, flea collars, shampoos, and dips.


Two studies in heartworm-infected dogs were conducted which demonstrated mild, transient hypersensitivity reactions in treated dogs with high microfilaremia counts (see Precautions for reactions observed). Safety studies in pregnant dogs demonstrated that high doses (1.5 mg/kg = 3X) of milbemycin oxime given in an exaggerated dosing regimen (daily from mating through weaning), resulted in measurable concentrations of the drug in milk. Puppies nursing these females which received exaggerated dosing regimens demonstrated milbemycin-related effects. These effects were directly attributable to the exaggerated experimental dosing regime. The product is normally intended for once-a-month administration only. Subsequent studies included using 3X daily from mating to one week before weaning and demonstrated no effects on the pregnant females or their litters. A second study where pregnant females were dosed once at 3X the monthly use rate either before, on the day of or shortly after whelping resulted in no effects on the puppies.


Some nursing puppies, at 2, 4, and 6 weeks of age, given greatly exaggerated oral doses of milbemycin oxime (9.6 mg/kg = 19X) exhibited signs typified by tremors, vocalization and ataxia. These effects were all transient and puppies returned to normal within 24 to 48 hours. No effects were observed in puppies given the recommended dose of milbemycin oxime (0.5 mg/kg). This product has not been tested in dogs less than 2.2 pounds in body weight.


A rising-dose safety study conducted in rough-coated collies manifested a clinical reaction consisting of ataxia, pyrexia and periodic recumbency in one of fourteen dogs treated with milbemycin oxime at 12.5 mg/kg (25X monthly use rate). Prior to receiving the 12.5 mg/kg dose (25X monthly use rate) on day 56 of the study, all animals had undergone an exaggerated dosing regimen consisting of 2.5 mg/kg milbemycin oxime (5X monthly use rate) on day 0, followed by 5.0 mg/kg (10X monthly use rate) on day 14 and 10.0 mg/kg (20X monthly use rate) on day 32. No adverse reactions were observed in any of the collies treated with this regimen up through the 10.0 mg/kg (20X monthly use rate) dose.



Safety: Lufenuron


Lufenuron tablets have been used and tested safely in over forty breeds of dogs, including pregnant females, breeding males and puppies over six weeks of age. In well-controlled clinical trials, 151 dogs completed treatment with lufenuron tablets. Lufenuron tablets were used safely in animals receiving frequently used veterinary products such as vaccines, anthelmintics, antibiotics and steroids. In a ten-month study, doses up to 10X the recommended dose rate of 10 mg/kg caused no overt toxicity. A single dose of 200 mg/kg (20X the recommended dose rate) had no marked effect on adult dogs, but caused decreased activity and appetite in eight week old puppies. Mean body weights of male and female puppies were higher in treated versus control group at the end of the study. In specifically designed target animal safety studies, lufenuron tablets were tested with concurrent administration of flea adulticids containing carbaryl, permethrin, chlorpyriphos and cythioate. No toxicity resulted from these combinations. Lufenuron tablets did not cause cholinesterase inhibition nor did they enhance cholinesterase inhibition caused by exposure to organophosphates.


Four reproductive safety studies were conducted in breeding dogs with lufenuron tablets: two laboratory and two well-controlled clinical studies. In one of the laboratory studies, where lufenuron was administered to beagle dogs at doses equivalent to 90X (3X daily) the monthly recommended dose of 10 mg/kg, the ratio of gravid females to females mated was 8/8 or 100% in the control group and 6/9 or 67% in the lufenuron-treated group. The mean number of pups per litter was two animals higher in the treated versus control groups and the mean birth weights of pups from treated bitches in this study was lower than control groups.


These pups grew at a similar rate to control pups. There was a higher incidence of four clinical signs in the lufenuron-treated versus control group: nasal discharge, pulmonary congestion, diarrhea/dehydration and sluggishness. The incidence of these signs was transient and decreasing by the end of lactation. Results from three additional reproductive safety studies, one laboratory and two clinical field studies evaluating eleven breeds of dogs, did not demonstrated any adverse finding for the reproductive parameters measured including fertility, pup birth weights and pup clinical signs after administration of lufenuron up to 5X the recommended monthly use rate.


Data from analysis of milk from lactating animals treated with lufenuron tablets of 2X and 6X the recommended monthly use rate demonstrates that lufenuron concentrates in the milk of these dogs. The average milk: blood concentration ratio was approximately 60 (i.e., 60X higher drug concentrations in the milk compared to drug levels in the blood of treated bitches). Nursing puppies averaged 8-9 times higher blood concentrations of lufenuron compared to their dams.



Dosage


Sentinel Flavor Tabs are given orally, once a month, at the recommended minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime and 4.55 mg/lb (10 mg/kg) lufenuron.


Dogs over 100 lbs are provided the appropriate combination of tablets.


*Please see separate insert in this package for concurrent dosing of Sentinel Flavor Tabs and CAPSTAR Tablets



Administration



TO ENSURE ADEQUATE ABSORPTION, ALWAYS ADMINISTER Sentinel Flavor Tabs TO DOGS IMMEDIATELY AFTER OR IN CONJUNCTION WITH A NORMAL MEAL.
















Recommended Dosage Schedule
Body WeightMilbemycin Oxime Per TabletLufenuron Per Tablet
2 to 10 lbs.2.3 mg46.0 mg
11 to 25 lbs.5.75 mg115 mg
26 to 50 lbs.11.5 mg230 mg
51 to 100 lbs.23.0 mg460 mg

Sentinel Flavor Tabs are palatable and most dogs will consume the tablet when offered by the owner. As an alternative to direct dosing, the tablets can be hidden in food. Be certain the dog consumes the entire tablet or tablets. Administer Sentinel Flavor Tabs to dogs immediately after or in conjunction with a normal meal. Food is essential for adequate absorption of lufenuron. Watch the dog closely following administration to be sure the entire dose have been consumed. If it is not entirely consumed, redose with the full recommended dose as soon as possible.


Sentinel Flavor Tabs must be administered monthly, preferably on the same date each month. Treatment with Sentinel Flavor Tabs may begin at any time of year. In geographic areas where mosquitoes and fleas are seasonal, the treatment schedule should begin one month prior to the expected onset and should continue until the end of “mosquito and flea season.” In areas with year-round infestations, treatment should continue through the entire year without interruption.


If a dose is missed and a 30-day interval between dosing is exceeded, administer Sentinel Flavor Tabs immediately and resume the monthly dosing schedule. If Sentinel Flavor Tabs replace daily diethylcarbamazine (DEC) for heartworm prevention, the first dose must be given within 30 days after the last dose of DEC.



Adverse Reactions


The following adverse reactions have been reported in dogs after giving milbemycin oxime or lufenuron: vomiting, depression/lethargy, pruitus, urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions, hypersalivation and weakness.



How Supplied


Sentinel Flavor Tabs are available in four tablet sizes, (see Dosage Section), formulated according to the weight of the dog. Each tablet size is available in color-coded packages of 6 or 12 tablets each, which are packaged 10 per display carton.



Storage Conditions


Store in a dry place at controlled room temperature, between 59º and 77ºF (15-25ºC).


Questions? Comments? Please Call 1-800-332-2761


Visit our website at www.petwellness.com


Manufactured for:      


Novartis Animal Health US, Inc.

Greensboro, NC 27408


NADA #141-084, Approved by FDA


©2007 Novarits Animal Health US, Inc.


SENTINEL, Flavor Tabs and CAPSTAR are registered trademarks of Novartis AG.



SENTINEL® (milbemycin oxime/lufenuron) Flavor Tabs®        Capstar® (nitenpyram)


FLEA MANAGEMENT SYSTEM


Supplemental Veterinary Package Insert


This insert describes the concurrent use of SENTINEL® (milbemycin oxime/lufenuron) Flavor Tabs® and CAPSTAR® (nitenpyram) Tablets for the management of fleas on dogs and puppies. Please read the insert contained in each package for complete information of the individual products prior to dispensing or dosing. The effects of Sentinel Flavor Tabs on heartworm disease and internal parasites are not described in this supplement.



Caution


Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.



Warnings


Not for human use. Keep this and all drugs out of the reach of children.



Indications


In dogs and puppies, the concurrent use of Sentinel Flavor Tabs and CAPSTAR Tablets is indicated to kill adult fleas and prevent eggs from hatching. The effects of Sentinel Flavor Tabs, which prevent and control flea populations, and CAPSTAR Tablets, which treat flea infestations are combined to provide a FLEA MANAGEMENT SYSTEM.



Step 1: Control


Give Sentinel Flavor Tabs once per month to prevent and control flea populations. Sentinel Flavor Tabs contain lufenuron. Lufenuron controls flea populations by preventing the development of flea eggs and does not kill adult fleas. If a dog currently has a flea infestation, more rapid relief can be accomplished by adding CAPSTAR to the treatment as follows.



Step 2: Kill Adult Fleas


If your pet Currently has a flea infestation, add CAPSTAR Tablets to kill adult fleas. CAPSTAR Tablets contain nitenpyram and are effective for treatment of flea infestations. Nitenpyram starts killing adult fleas within 30 minutes of administration.


  • Administer CAPSTAR Tablets once per week until adult fleas are no longer observed.

  • For a severe flea infestation, administer CAPSTAR Tablets twice per week until adult fleas are no longer observed.

  • Additional CAPSTAR Tablets may be administered as needed to kill the occasional adult flea picked up from infested environments.

  • It is important to treat all cats and dogs in the household. All cats should be treated with approved products like lufenuron in combination with nitenpyram as needed. Fleas can reproduce on untreated pets and allow infestations to persist.


Dosage


The combination of Sentinel Flavor Tabs and CAPSTAR Tablets should be administered according to the following schedule. Weigh your dog prior to administration to ensure proper dosage. Do not administer to dogs under 2 pounds.



























Recommended Dosage Schedule
Body WeightDoseCAPSTAR Once or twice weekly* (Nitenpyram per tablet)Sentinel Flavor Tabs once per month (Lufenuron per tablet)
2 to 10 lbs.One Tablet11.446.0 mg
11 to 25 lbs.One Tablet11.4115 mg
26 to 50 lbs.One Tablet57.0230 mg
51 to 100 lbs.One Tablet57.0460 mg
101 to 125 lbs.One Tablet57.0**

*If adult fleas are seen


**Dogs over 100 lbs. are provided the appropriate combination of Sentinel Flavor Tabs.



Precautions


The safety of the concurrent use of Sentinel Flavor Tabs and CAPSTAR Tablets in pregnant or nursing dogs or in puppies less than 11 weeks of age has not been demonstrated.



Adverse Reactions


The following adverse reactions have been reported in dogs after giving Sentinel Flavor Tabs: vomiting, depression/lethargy, pruritus, urticaria, diarrhea, anorexia, skin congestion, ataxia, convulsions, hypersalivation and weakness.



Effectiveness


Please refer to the labeling for Sentinel Flavor Tabs and CAPSTAR Tablets for information about the effectiveness of each product. Studies testing the concurrent use of the two products demonstrated that each product remains effective for its labeled indication when both are administered concurrently. In a simulated home environment, the administration of Sentinel Flavor Tabs monthly and CAPSTAR either once or twice weekly demonstrated a greater and more rapid reduction of established flea infestations than Sentinel Flavor Tabs alone.



Animal Safety


The combination of nitenpyram, milbemycin oxime and lufenuron has been tested in a 90 day laboratory study. Administration of 5X the recommended use rate of CAPSTAR Tablets for 90 consecutive days, concurrently with administration of 5X the recommended use rate of Sentinel Flavor Tabs every 2 weeks for 7 treatments was well tolerated.



Flea Infestations on Dogs


In addition to the common nuisance irritations associated with infestations, fleas can be responsible for skin conditions in the dog such as flea allergy dermatitis. Fleas also transmit other parasites, including tapeworms. The control of flea infestations reduces the problems associated with these parasites.


Sentinel Flavor Tabs break the flea life cycle by inhibiting egg development. CAPSTAR Tablets rapidly kill adult fleas on the dog. The concurrent use of these two products provides an effective flea management system.


The following diagram illustrates the flea’s life cycle and where the combination of Sentinel Flavor Tabs and CAPSTAR Tablets work:


Life Cycle of the Flea



A single female flea may produce up to 2,000 eggs over her lifetime. Eggs hatch and can develop into adults within only three weeks. Adult female fleas feed by ingesting blood from the pet and subsequently lay eggs, which drop off the pet’s coat. Within days, larvae hatch from the eggs and live undetected in the pet’s surroundings, such as the carpet and bedding. Flea larvae spin a cocoon, and when appropriately stimulated, a young adult flea emerges and jumps onto the pet to continue the life cycle.


After reading this insert, if you have any questions about the concurrent use of Sentinel Flavor Tabs and CAPSTAR Tablets for your patients, please call Novartis Animal Health US, Inc. Veterinary Product Support at 1 (800)-332-2761.



Storage Conditions


Store Sentinel Flavor Tabs and CAPSTAR Tablets as described on the individual product inserts.


Questions? Comments?


Please Call 1-800-332-2761


Visit our website at www.petwellness.com


Manufactured for:      


Novartis Animal Health US, Inc.

Greensboro, NC 27408


NADA 141-204, Approved by FDA.


©2007 Novartis Animal Health US, Inc.


SENTINEL, Flavor Tabs and CAPSTAR are registered trademarks of Novartis AG.


NAH/SEN-FT/VIPI-FMS/2


12/07



PRINCIPAL DISPLAY PANEL


Package Label - 2.3 mg milbemycin oxime / 46 mg lufenuron


Recommended for dogs and puppies


2-10lbs.


NOVARTIS


ANIMAL HEALTH


Sentinel® flavor tabs® 


(milbemycin oxime • lufenuron)


Once-a-month flavored tablets


6 PACK


Give with a meal


 




PRINCIPAL DISPLAY PANEL


Package Label - 5.75 mg milbemycin oxime / 115 mg lufenuron


Recommended for dogs and puppies


11-25lbs.


NOVARTIS


ANIMAL HEALTH


Sentinel® flavor tabs® 


(milbemycin oxime • lufenuron)


Once-a-month flavored tablets


6 PACK


Prevents Heartworm Disease


and Flea Populations in Dogs and Puppies


Also controls flea populations, adult hookworm


infections, removes and controls adult roundworm


and whipworm infections in dogs and puppies.


Keep this and all drugs out of the reach of children.


Net contents: 6 tablets, 5.75 mg milbemycin oxime


and 115 mg lufenuron each.


Give with a meal


Caution: Federal (USA) law restricts


this drug to use by or on the order


of a licensed veterinarian.


Product # 52221 NADA # 141-084


Approved by FDA




PRINCIPAL DISPLAY PANEL


Package Label – 11.5 mg milbemycin oxime / 230 mg lufenuron


Recommended for dogs and puppies


26-50lbs.


NOVARTIS


ANIMAL HEALTH


Sentinel® flavor tabs® 


(milbemycin oxime • lufenuron)


Once-a-month flavored tablets


6 PACK


Prevents Heartworm Disease


and Flea Populations in Dogs and Puppies


Also controls flea populations, adult hookworm


infections, removes and controls adult roundworm


and whipworm infections in dogs and puppies.


Keep this and all drugs out of the reach of children.


Net contents: 6 tablets, 11.5 mg milbemycin oxime


and 230 mg lufenuron each.


Give with a meal


Caution: Federal (USA) law restricts


this drug to use by or on the order


of a licensed veterinarian.


Product # 52231 NADA # 141-084


Approved by FDA




PRINCIPAL DISPLAY PANEL


Package Label – 23 mg milbemycin oxime / 460 mg lufenuron


NOVARTIS


ANIMAL HEALTH


Sentinel® flavor tabs® 


(milbemycin oxime • lufenuron)


Once-a-month flavored tablets


6 PACK


Prevents Heartworm Disease


and Flea Populations in Dogs and Puppies


Also controls flea populations, adult hookworm


infections, removes and controls adult roundworm


and whipworm infections in dogs and puppies.


Keep this and all drugs out of the reach of children.


Net contents: 6 tablets, 23 mg milbemycin oxime


and 460 mg lufenuron each.


Give with a meal


Caution: Federal (USA) law restricts


this drug to use by or on the order


of a licensed veterinarian.


Product # 52241 NADA # 141-084


Approved by FDA










Sentinel Flavor Tabs 
milbemycin oxime and lufenuron  tablet, coated










Product Information
Product TypePRESCRIPTION ANIMAL DRUGNDC Product Code (Source)58198-5221
Route of AdministrationORALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MILBEMYCIN OXIME (MILBEMYCIN OXIME)MILBEMYCIN OXIME2.3 mg
LUFENURON (LUFENURON)LUFENURON46 mg





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
ColorBROWNScoreno score
ShapePENTAGON (5 SIDED) (biconvnex bevel-edges)Size7mm
FlavorMEAT (beef flavor)Imprint CodeCD;CGV
Contains      






















Packaging
#NDCPackage DescriptionMultilevel Packaging
158198-5221-11 BLISTER PACK In 1 BOXcontains a BLISTER PACK
16 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5221-1)
258198-5221-32 BLISTER PACK In 1 BOXcontains a BLISTER PACK
26 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5221-3)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14108401/05/2000







Sentinel Flavor Tabs 
milbemycin oxime and lufenuron  tablet, coated










Product Information
Product TypePRESCRIPTION ANIMAL DRUGNDC Product Code (Source)58198-5222
Route of AdministrationORALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MILBEMYCIN OXIME (MILBEMYCIN OXIME)MILBEMYCIN OXIME5.75 mg
LUFENURON (LUFENURON)LUFENURON115 mg





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
ColorBROWNScoreno score
ShapePENTAGON (5 SIDED) (biconvnex bevel-edges)Size10mm
FlavorMEAT (beef flavor)Imprint CodeGNG;CGV
Contains      






















Packaging
#NDCPackage DescriptionMultilevel Packaging
158198-5222-11 BLISTER PACK In 1 BOXcontains a BLISTER PACK
16 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5222-1)
258198-5222-32 BLISTER PACK In 1 BOXcontains a BLISTER PACK
26 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5222-3)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14108401/05/2000







Sentinel Flavor Tabs 
milbemycin oxime and lufenuron  tablet, coated










Product Information
Product TypePRESCRIPTION ANIMAL DRUGNDC Product Code (Source)58198-5223
Route of AdministrationORALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MILBEMYCIN OXIME (MILBEMYCIN OXIME)MILBEMYCIN OXIME11.5 mg
LUFENURON (LUFENURON)LUFENURON230 mg





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
ColorBROWNScoreno score
ShapePENTAGON (5 SIDED) (biconvnex bevel-edges)Size12mm
FlavorMEAT (beef flavor)Imprint CodeGLG;CGV
Contains      






















Packaging
#NDCPackage DescriptionMultilevel Packaging
158198-5223-11 BLISTER PACK In 1 BOXcontains a BLISTER PACK
16 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5223-1)
258198-5223-32 BLISTER PACK In 1 BOXcontains a BLISTER PACK
26 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5223-3)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14108401/05/2000







Sentinel Flavor Tabs 
milbemycin oxime and lufenuron  tablet, coated










Product Information
Product TypePRESCRIPTION ANIMAL DRUGNDC Product Code (Source)58198-5224
Route of AdministrationORALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MILBEMYCIN OXIME (MILBEMYCIN OXIME)MILBEMYCIN OXIME23 mg
LUFENURON (LUFENURON)LUFENURON460 mg





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
ColorBROWNScoreno score
ShapePENTAGON (5 SIDED) (biconvnex bevel-edges)Size16mm
FlavorMEAT (Beef flavor)Imprint CodeGKG;CGV
Contains      






















Packaging
#NDCPackage DescriptionMultilevel Packaging
158198-5224-11 BLISTER PACK In 1 BOXcontains a BLISTER PACK
16 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5224-1)
258198-5224-32 BLISTER PACK In 1 BOXcontains a BLISTER PACK
26 TABLET In 1 BLISTER PACKThis package is contained within the BOX (58198-5224-3)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NADANADA14108401/05/2000


Labeler - Novartis Animal Health US, Inc. (966985624)
Revised: 12/2009Novartis Animal Health US, Inc.

Friday, 4 May 2012

Simuc-GP


Generic Name: guaifenesin and phenylephrine (gwye FEN e sin and FEN il EFF rin)

Brand Names: Aldex G, Aquatab D, Crantex, D-Phen 1000, D-Tab, Deconex, Deconsal II, Deconsal Pediatric, Despec, Donatussin Drops, Duomax, Duraphen 1000, Duraphen II, Duratuss, Dynex LA, ExeTuss, Extendryl G, Fenesin PE IR, Genexa LA, Gentex LA, Gilphex TR, Guaiphen-D 1200, Guaiphen-D 600, Guaiphen-PD, Guiadex PD, Guiatex PE, J-Max, Liquibid D-R, Liquibid-D, Liquibid-PD, Lusonex, Maxiphen, Medent-PE, MontePhen, Mucinex Children's Cold, Mucus Relief Sinus, Mydex, Nariz, Nasex, Nescon-PD, Nexphen PD, Norel EX, PE-Guai, Pendex, Prolex D, Refenesen PE, Reluri, Rescon-GG, Respa-PE, Robitussin Head & Chest Congestion, Simuc, Simuc-GP, Sina-12X, Sinupan, SINUvent PE, Sitrex PD, Sudafed PE Non-Drying Sinus, Sudex, Triaminic Chest & Nasal Congestion, Visonex, Wellbid-D, Xedec, Xedec II, Xpect-PE, Zotex GPX


What is Simuc-GP (guaifenesin and phenylephrine)?

There are many brands and forms of guaifenesin and phenylephrine available and not all brands are listed on this leaflet.


Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.


Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of guaifenesin and phenylephrine is used to treat stuffy nose and sinus congestion, and to reduce chest congestion caused by the common cold or flu.


Guaifenesin and phenylephrine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Simuc-GP (guaifenesin and phenylephrine)?


There are many brands and forms of guaifenesin and phenylephrine available and not all brands are listed on this leaflet.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Ask a doctor or pharmacist before using any other cough, cold, or allergy medicine. Guaifenesin and phenylephrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or phenylephrine.

What should I discuss with my healthcare provider before taking Simuc-GP (guaifenesin and phenylephrine)?


You should not use this medication if you are allergic to guaifenesin or phenylephrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use guaifenesin and phenylephrine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. Serious, life threatening side effects can occur if you use guaifenesin and phenylephrine before the MAO inhibitor has cleared from your body.

Ask a doctor or pharmacist if it is safe for you to take this medication if you have:



  • heart disease or high blood pressure;




  • diabetes;




  • circulation problems;




  • glaucoma;




  • overactive thyroid; or




  • enlarged prostate or problems with urination.




It is not known if this medication may be harmful to an unborn baby. Do not use this medication without your doctor's advice if you are pregnant. This medication passes into breast milk and could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Artificially-sweetened liquid forms of cold medicine may contain phenylalanine. This would be important to know if you have phenylketonuria (PKU). Check the ingredients and warnings on the medication label if you are concerned about phenylalanine.


How should I take Simuc-GP (guaifenesin and phenylephrine)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cold medicine is usually taken only for a short time until your symptoms clear up.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving cough or cold medicine to a child. Death can occur from the misuse of cough or cold medicine in very young children.

Measure the liquid form of this medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Do not crush, chew, break, or open an extended-release tablet or capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time. Take guaifenesin and phenylephrine with food if it upsets your stomach. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash. Drink extra fluids to help loosen the congestion and lubricate your throat while you are taking this medication. Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Since cough or cold medicine is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, vomiting, numbness or tingly feeling, dizziness, and feeling restless or nervous.


What should I avoid while taking Simuc-GP (guaifenesin and phenylephrine)?


This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of guaifenesin and phenylephrine. Ask a doctor or pharmacist before using any other cough, cold, or allergy medicine. Guaifenesin and phenylephrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or phenylephrine.

Avoid taking this medication with diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor's advice. Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.


Simuc-GP (guaifenesin and phenylephrine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:

  • fast, pounding, or uneven heartbeat;




  • severe dizziness, anxiety, restless feeling, or nervousness;




  • easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms;




  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure); or




  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).



Less serious side effects may include:



  • vomiting, upset stomach;




  • warmth, tingling, or redness under your skin;




  • feeling excited or restless (especially in children);




  • sleep problems (insomnia);




  • skin rash or itching;




  • headache; or




  • dizziness.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Simuc-GP (guaifenesin and phenylephrine)?


Ask a doctor or pharmacist if it is safe for you to take guaifenesin and phenylephrine if you are also using any of the following drugs:



  • medicines to treat high blood pressure;




  • a beta-blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Dutoprol, Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), and others; or




  • an antidepressant such as amitriptyline (Elavil, Vanatrip, Limbitrol), doxepin (Sinequan, Silenor), desipramine (Norpramin), imipramine (Janimine, Tofranil), nortriptyline (Pamelor), and others.



This list is not complete and other drugs may interact with guaifenesin and phenylephrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Simuc-GP resources


  • Simuc-GP Side Effects (in more detail)
  • Simuc-GP Use in Pregnancy & Breastfeeding
  • Simuc-GP Drug Interactions
  • Simuc-GP Support Group
  • 0 Reviews for Simuc-GP - Add your own review/rating


  • Crantex Prescribing Information (FDA)

  • Despec Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Entex LA Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Gentex LA Sustained-Release Tablets (12 Hour) MedFacts Consumer Leaflet (Wolters Kluwer)

  • Guiatex PE Prescribing Information (FDA)

  • Lusonex Controlled-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Rescon-GG Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • Sina-12X Suspension MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Simuc-GP with other medications


  • Cough and Nasal Congestion
  • Sinus Symptoms


Where can I get more information?


  • Your pharmacist can provide more information about guaifenesin and phenylephrine.

See also: Simuc-GP side effects (in more detail)


Tuesday, 1 May 2012

Wolff-Parkinson-White Syndrome Medications


Definition of Wolff-Parkinson-White Syndrome: This syndrome involves episodes of rapid heart rate (tachycardia) caused by abnormal electrical pathways (circuits) in the heart.

Drugs associated with Wolff-Parkinson-White Syndrome

The following drugs and medications are in some way related to, or used in the treatment of Wolff-Parkinson-White Syndrome. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Wolff-Parkinson-White Syndrome





Drug List: